{
    "ticker": "RCKT",
    "name": "Rocket Pharmaceuticals, Inc.",
    "description": "Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing and commercializing transformative gene therapies for rare genetic diseases. Founded in 2015, Rocket's innovative approach leverages its proprietary adeno-associated virus (AAV) platform and extensive expertise in gene therapy to address severe and life-threatening conditions. The company is dedicated to delivering impactful treatments for patients with limited options, particularly in the areas of hematology and oncology. Notable programs include its lead product candidate, RP-L102, which is designed to treat Fanconi Anemia, and RP-L201 for the treatment of Pyruvate Kinase Deficiency. Rocket\u2019s commitment to advancing gene therapy is underscored by its robust pipeline and collaborations with leading institutions, enabling the company to push the boundaries of science and medicine. With a mission to provide hope and improve the quality of life for patients and their families, Rocket Pharmaceuticals is at the forefront of the biopharmaceutical industry, aspiring to revolutionize the treatment landscape for rare genetic diseases.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Cranbury, New Jersey, USA",
    "founded": "2015",
    "website": "https://www.rocketpharma.com",
    "ceo": "Garry N. Neil",
    "social_media": {
        "twitter": "https://twitter.com/RocketPharma",
        "linkedin": "https://www.linkedin.com/company/rocket-pharmaceuticals"
    },
    "investor_relations": "https://investors.rocketpharma.com",
    "key_executives": [
        {
            "name": "Garry N. Neil",
            "position": "CEO"
        },
        {
            "name": "Peter J. Trachtenberg",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Gene Therapies",
            "products": [
                "RP-L102",
                "RP-L201"
            ]
        }
    ],
    "seo": {
        "meta_title": "Rocket Pharmaceuticals, Inc. | Transformative Gene Therapies",
        "meta_description": "Explore Rocket Pharmaceuticals, Inc., a leader in developing gene therapies for rare genetic diseases. Learn about innovative treatments and the company's mission.",
        "keywords": [
            "Rocket Pharmaceuticals",
            "Gene Therapy",
            "Biotechnology",
            "Rare Diseases",
            "RP-L102",
            "RP-L201"
        ]
    },
    "faq": [
        {
            "question": "What does Rocket Pharmaceuticals focus on?",
            "answer": "Rocket Pharmaceuticals focuses on developing gene therapies for rare genetic diseases."
        },
        {
            "question": "Who is the CEO of Rocket Pharmaceuticals?",
            "answer": "Garry N. Neil is the CEO of Rocket Pharmaceuticals, Inc."
        },
        {
            "question": "Where is Rocket Pharmaceuticals headquartered?",
            "answer": "Rocket Pharmaceuticals is headquartered in Cranbury, New Jersey, USA."
        },
        {
            "question": "What are some of Rocket's key products?",
            "answer": "Rocket's key products include RP-L102 for Fanconi Anemia and RP-L201 for Pyruvate Kinase Deficiency."
        },
        {
            "question": "When was Rocket Pharmaceuticals founded?",
            "answer": "Rocket Pharmaceuticals was founded in 2015."
        }
    ],
    "competitors": [
        "EDIT",
        "AVTX",
        "CRSP",
        "SGMO"
    ],
    "related_stocks": [
        "AMGN",
        "REGN",
        "BIIB",
        "VRTX"
    ]
}